Icade is down more than 3% in Paris, as Invest Securities maintains its buy rating on the stock, with a price target reduced from 57.2 to 55.1 euros.

The research firm reports that the sale of all Icade's healthcare assets will take place in 3 phases, spread over the period up to 2025.

Given the strong demand for healthcare assets and the benchmark set by phase 1, we model a discount of -5% on asset valuations for phases 2 and 3. The main buyer, Primonial, is not legally obliged to acquire the assets in phases 2 and 3, which could potentially complicate transactions", the analyst points out.

However, Invesr remains confident in the successful completion of the 3 phases, which will generate excessive cash flow (E3 billion) for a wide range of potential uses.

The operation is positive in the short term, with the prospect of cumulative dividends from 2023 to 2025 of almost 44% of the current share price, but in the medium term it will leave Icade at the head of a less diversified and clearly less attractive portfolio, with a sharply reduced normative dividend (-18%)", concludes the analyst.


Copyright (c) 2023 CercleFinance.com. All rights reserved.